Cadila gets USFDA nod for Diltiazem Hydrochloride capsules
DSIJ Intelligence / 09 Aug 2017
Zydus Cadila has received final approval from the USFDA to market Diltiazem Hydrochloride extended-release capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg and 360 mg.
Zydus Cadila has received final approval from the USFDA to market Diltiazem Hydrochloride extended-release capsules USP in strengths of 120 mg, 180 mg, 240 mg, 300 mg and 360 mg. The drug is used in the treatment of hypertension (high blood pressure), angina (chest pain) and certain heart rhythm disorders.
It will be produced at the group’s formulation manufacturing facility at the Pharma SEZ in Ahmedabad. The sales of Diltiazem Hydrochloride capsules are estimated at USD 191 million. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY04.
Meanwhile, the stock traded in the negative territory, slipping 2.61% at Rs 516.30 per share on the BSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.